EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database

Yinjing Hou, Xiayang Ren iD, Ying Chen, Yanfeng Wang

Expert Opinion on Drug Safety · 2025

DOI: 10.1080/14740338.2024.2392003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Expert Opinion on Drug Safety, 2025. Verfasst von Yinjing Hou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Cardiovascular Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the program of Beijing Hope Run Special Fund of Cancer Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Selective RET-specific tyrosine kinase inhibitors (RET-TKIs) treat RET fusion-positive non-small cell lung cancer (NSCLC), but studies on their cardiovascular toxicities are limited. This study aimed to characterize the cardiovascular toxicities associated with selective RET-TKI in real-world settings. RESEARCH DESIGN AND METHODS: Data from the United States Food and Drug Administration Adverse Event Reporting System database from 1 January 2020 to 30 June 2023, were analyzed. Two disproportionality methods, information component and reporting odds ratio (ROR) were used. RESULTS: Both pralsetinib and selpercatinib showed positive signals for hypertension (pralsetinib: ROR: 5.25, 95% CI: 4.40-6.26; selpercatinib: ROR: 2.68, 95% CI: 1.87-3.82). Additionally, pralsetinib showed a positive signal for ischemic heart disease (ROR: 3.92, 95% CI: 2.94-5.23), and selpercatinib for torsade de pointes/QT prolongation (ROR: 2.65, 95% CI: 1.74-4.04). The median time to onset(TTO) of cardiovascular toxicities was 33 days (IQR: 9-73 days) for pralsetinib and 15 days (IQR: 10-50 days) for selpercatinib. The proportion of deaths, life-threatening events, and hospitalizations due to cardiovascular toxicities were 8.57%, 1.19%, and 31.43%, respectively, for total selective RET-TKI. CONCLUSIONS: Selective RET-TKIs are related to multiple cardiovascular toxicities. Pralsetinib was linked to ischemic heart disease, and selpercatinib to torsade de pointes/QT prolongation and thrombotic events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsCardiovascular DiseasesHumansAdverse Drug Reaction Reporting SystemsPharmacovigilanceUnited StatesUnited States Food and Drug AdministrationDatabases, FactualProto-Oncogene Proteins c-retCarcinoma, Non-Small-Cell LungFemaleMaleMiddle AgedLung NeoplasmsPyrazolesAgedPyrimidinesAntineoplastic AgentsAdultPyridinesPiperidinesTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

Cardiovascular toxicitiesFood and Drug Administration Adverse Event Reporting SystemSelective ret-specific tyrosine kinase inhibitorsdisproportionality analysisnon-small cell lung cancer

Substanzen

Protein Kinase InhibitorsProto-Oncogene Proteins c-retPyrazolespralsetinibselpercatinibRET protein, humanPyrimidinesAntineoplastic AgentsPyridinesPiperidines

Autor:innen und Institutionen

  • Department of Geriatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
  • Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

ORCID-Profile: Xiayang Ren

Förderung

  • the program of Beijing Hope Run Special Fund of Cancer Foundation of China

Zitieren

APA

Hou, Y., Ren, X., Chen, Y., & Wang, Y. (2025). Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2024.2392003

Vancouver

Hou Y, Ren X, Chen Y, Wang Y. Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database. Expert Opinion on Drug Safety. 2025. doi:10.1080/14740338.2024.2392003

BibTeX
@article{Hou2025,
  author = {Hou, Yinjing and Ren, Xiayang and Chen, Ying and Wang, Yanfeng},
  title = {Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database},
  journal = {Expert Opinion on Drug Safety},
  year = {2025},
  doi = {10.1080/14740338.2024.2392003}
}
Kostenlos starten →